Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

relapsed and refractory multiple myeloma

- PMLiVE

EU aims to vaccinate 40% of population in initial COVID-19 blueprint

Target is double the goal set by the World Health Organization

- PMLiVE

COVID-19 vaccine deals with the EU hindered by strict liability rules

Companies would retain liability for unexpected side effects

- PMLiVE

EU concludes discussions with Moderna for COVID-19 vaccine

Biotech company on the verge on finalising supply deal

- PMLiVE

J&J inks $6.5bn all-cash deal to acquire Momenta

Acquisition sees J&J gain access to portfolio of autoimmune disease treatments

AstraZeneca AZ

AZ inks deal with EU for 400 million doses of COVID-19 vaccine

Doses will be available to all EU member states at no profit during pandemic

- PMLiVE

UK agrees on COVID-19 vaccine deals with J&J and Novavax

Initial agreement secures 90 million doses

- PMLiVE

EU grants approval for Venclyxto/Gazyvaro combo in CLL

Chemotherapy-free option for previously-untreated patients

- PMLiVE

UPDATED: J&J expands US partnership for coronavirus treatments

Expands on exisiting alliance announced last week

- PMLiVE

GSK and Gilead join global efforts to tackle novel coronavirus

Confirmed cases rise to over 17,000 in China

- PMLiVE

J&J begins search for a coronavirus vaccine as confirmed cases rise

Death toll has now reached 170, with 7,711 confirmed cases in China

- PMLiVE

J&J gets EMA nod for wider use of Erleada in prostate cancer

Maintains a regulatory lead over rival Xtandi

- PMLiVE

NICE knocks back J&J’s depression nasal spray Spravato

Cites clinical and pricing uncertainty as basis of rejection

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links